119 related articles for article (PubMed ID: 26799234)
1. Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study.
Bachy E; Estell JA; Van de Neste E; Bouabdallah R; Bargay J; Delmer A; Gelas-Dore B; Gomes da Silva M; Fitoussi O; Belada D; Maisonneuve H; Intragumtornchai T; Lamy T; Dartigues P; Seymour JF; Salles G
Am J Hematol; 2016 Jun; 91(4):410-5. PubMed ID: 26799234
[TBL] [Abstract][Full Text] [Related]
2. Relationships between chemotherapy, chemotherapy dose intensity and outcomes of follicular lymphoma in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence Molecular Epidemiology Resource.
Wudhikarn K; Smith BJ; Button AM; Habermann TM; Thompson CA; Rosenstein LJ; Syrbu SI; Weiner GJ; Cerhan JR; Link BK
Leuk Lymphoma; 2015; 56(8):2365-72. PubMed ID: 25530345
[TBL] [Abstract][Full Text] [Related]
3. Absolute monocyte count in follicular lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Watanabe R; Tomita N; Kishimoto K; Koyama S; Ogusa E; Ishii Y; Miyashita K; Matsuura S; Fujisawa S; Hattori Y; Takasaki H; Fujita A; Ohshima R; Kuwabara H; Hashimoto C; Fujimaki K; Sakai R; Ishigatsubo Y
Leuk Res; 2013 Oct; 37(10):1208-12. PubMed ID: 23927994
[TBL] [Abstract][Full Text] [Related]
4. Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP.
Samaras P; Heider H; Haile SR; Petrausch U; Schaefer NG; Siciliano RD; Meisel A; Mischo A; Zweifel M; Knuth A; Stenner-Liewen F; Renner C
Ann Hematol; 2010 Aug; 89(8):783-7. PubMed ID: 20204361
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Treatment in Slovene Follicular Lymphoma Patients.
Južnič Šetina T; Borštnar S; Jezeršek Novaković B
Clin Lymphoma Myeloma Leuk; 2015 Oct; 15(10):586-91. PubMed ID: 26423702
[TBL] [Abstract][Full Text] [Related]
6. Rituximab Improves the Outcome of Patients With Grade 3 Follicular Lymphoma Receiving Anthracycline-Based Therapy.
Yuan J; Greiner TC; Fu K; Smith LM; Aoun P; Chan WC; Bierman PJ; Bociek RG; Vose JM; Armitage JO; Weisenburger DD
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):488-497.e2. PubMed ID: 28842137
[TBL] [Abstract][Full Text] [Related]
7. Frontline intensive chemotherapy improves outcome in young, high-risk patients with follicular lymphoma: pair-matched analysis from the Czech Lymphoma Study Group Database.
Procházka V; Papajík T; Janíková A; Belada D; Kozák T; Šálek D; Sýkorová A; Móciková H; Campr V; Dlouhá J; Langová K; Fürst T; Trněný M
Leuk Lymphoma; 2017 Mar; 58(3):601-613. PubMed ID: 27666539
[TBL] [Abstract][Full Text] [Related]
8. Identification of MUM1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis.
Xerri L; Bachy E; Fabiani B; Canioni D; Chassagne-Clément C; Dartigues-Cuilléres P; Charlotte F; Brousse N; Rousselet MC; Foussard C; Brice P; Feugier P; Morschhauser F; Sonet A; Olive D; Salles G;
Hum Pathol; 2014 Oct; 45(10):2085-93. PubMed ID: 25149549
[TBL] [Abstract][Full Text] [Related]
9. Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma.
Zhou X; Wang J; Zhang J; Copley-Merriman C; Torigoe Y; Reyes C; Seymour JF; Offner FC; Trneny M; Salles GA
Hematology; 2015 Apr; 20(3):129-36. PubMed ID: 25029908
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte.
Bachy E; Brice P; Delarue R; Brousse N; Haioun C; Le Gouill S; Delmer A; Bordessoule D; Tilly H; Corront B; Allard C; Foussard C; Bosly A; Coiffier B; Gisselbrecht C; Solal-Celigny P; Salles G
J Clin Oncol; 2010 Feb; 28(5):822-9. PubMed ID: 20026809
[TBL] [Abstract][Full Text] [Related]
11. Clinico-biological features, treatment and survival of 457 patients with histological Grades 3A and 1-2 follicular lymphoma mostly treated with immunochemotherapy.
Mercadal S; Pomares H; Sancho JM; Climent F; García O; Encuentra M; Domingo-Doménech E; Sorigué M; Moreno M; Oliveira AC; Ribera JM; Fernández de Sevilla A; González-Barca E
Br J Haematol; 2016 Feb; 172(3):470-3. PubMed ID: 26010479
[No Abstract] [Full Text] [Related]
12. Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era.
Nowakowski GS; Maurer MJ; Habermann TM; Ansell SM; Macon WR; Ristow KM; Allmer C; Slager SL; Witzig TE; Cerhan JR
J Clin Oncol; 2010 Jan; 28(3):412-7. PubMed ID: 20008638
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
[TBL] [Abstract][Full Text] [Related]
14. Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis.
Sarkozy C; Baseggio L; Feugier P; Callet-Bauchu E; Karlin L; Seymour JF; Lebras L; Michallet AS; Offner F; Dumas O; Traverse-Glehen A; Ffrench M; Lopez-Guillermo A; Berger F; Coiffier B; Felman P; Salles G
Br J Haematol; 2014 Mar; 164(5):659-67. PubMed ID: 24274024
[TBL] [Abstract][Full Text] [Related]
15. Statin use and survival in 16 098 patients with non-Hodgkin lymphoma or chronic lymphocytic leukaemia treated in the rituximab era.
Brånvall E; Ekberg S; Eloranta S; Wästerlid T; Birmann BM; Smedby KE
Br J Haematol; 2021 Nov; 195(4):552-560. PubMed ID: 34331461
[TBL] [Abstract][Full Text] [Related]
16. Impact of prior treatment on outcome of transformed follicular lymphoma and relapsed de novo diffuse large B cell lymphoma: a retrospective multicentre analysis.
Lerch K; Meyer AH; Stroux A; Hirt C; Keller U; Viardot A; Marks R; Schreiber S; Pezzutto A; Scholz CW
Ann Hematol; 2015 Jun; 94(6):981-8. PubMed ID: 25645656
[TBL] [Abstract][Full Text] [Related]
17. New treatment options have changed the survival of patients with follicular lymphoma.
Fisher RI; LeBlanc M; Press OW; Maloney DG; Unger JM; Miller TP
J Clin Oncol; 2005 Nov; 23(33):8447-52. PubMed ID: 16230674
[TBL] [Abstract][Full Text] [Related]
18. The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: retrospective study of the Intergruppo Italiano Linfomi on 761 cases.
Rigacci L; Federico M; Martelli M; Zinzani PL; Cavanna L; Bellesi G; Merli F; Alterini R; Petrucci MT; Tani M; Liberati AM; Vitolo U; Pavone V; Cuneo A; Chisesib T; Brugiatelli M;
Leuk Lymphoma; 2003 Nov; 44(11):1911-7. PubMed ID: 14738142
[TBL] [Abstract][Full Text] [Related]
19. Fludarabine, cyclophosphamide and rituximab as first-line treatment in patients with newly diagnosed follicular lymphoma.
De la Cruz Vicente F; Carrillo-Cruz E; Rodriguez MS; Marín Niebla A; Galiana ML; Gonzalez JF; Cuadrado IM; Campos JG; Tocino IE; Rios-Herranz E; Perez-Simón JA
Eur J Haematol; 2014 Dec; 93(6):469-75. PubMed ID: 24853381
[TBL] [Abstract][Full Text] [Related]
20. Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome.
Sorigue M; Mercadal S; Alonso S; Fernández-Álvarez R; García O; Moreno M; Pomares H; Alcoceba M; González-García E; Motlló C; González-Barca E; Martin A; Sureda A; Caballero D; Ribera JM; Sancho JM
Hematol Oncol; 2017 Dec; 35(4):520-527. PubMed ID: 28156010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
